Healthcare -
Biotechnology - NASDAQ - US
$ 5.89
0.341 %
$ 301 M
Market Cap
-9.35
P/E
1. INTRINSIC VALUE
Balance Sheet
Abeona Therapeutics Inc.
| Current Assets | 101 M |
| Cash & Short-Term Investments | 97.7 M |
| Receivables | 1.65 M |
| Other Current Assets | 1.48 M |
| Non-Current Assets | 8.08 M |
| Long-Term Investments | 0 |
| PP&E | 7.98 M |
| Other Non-Current Assets | 96 K |
| Current Liabilities | 16.6 M |
| Accounts Payable | 3.44 M |
| Short-Term Debt | 6.75 M |
| Other Current Liabilities | 6.4 M |
| Non-Current Liabilities | 48.3 M |
| Long-Term Debt | 16.3 M |
| Other Non-Current Liabilities | 32 M |
EFFICIENCY
Earnings Waterfall
Abeona Therapeutics Inc.
| Revenue | 0 |
| Cost Of Revenue | 2.91 M |
| Gross Profit | -2.91 M |
| Operating Expenses | 64.2 M |
| Operating Income | -64.2 M |
| Other Expenses | -477 K |
| Net Income | -63.7 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Abeona Therapeutics Inc.
| Net Income | -63.7 M |
| Depreciation & Amortization | 2.91 M |
| Capital Expenditures | -2.45 M |
| Stock-Based Compensation | 6.63 M |
| Change in Working Capital | -4.38 M |
| Others | 885 K |
| Free Cash Flow | -58.5 M |
Wall Street Analysts Price Targets
Abeona Therapeutics Inc.
Wall Street analysts predict an average 1-year price target for ABEO of $15.6 , with forecasts ranging from
a
low of
$6 to a high of $20 .
ABEO Lowest Price Target
Wall Street Target
6 USD
1.87%
ABEO Average Price Target
Wall Street Target
15.6 USD
164.86%
ABEO Highest Price Target
Wall Street Target
20 USD
239.56%
4. DIVIDEND
ANALYSIS
ABEO does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Abeona Therapeutics Inc.
Sold
0-3 MONTHS
592 K USD 4
3-6 MONTHS
161 K USD 2
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million
Cash resources totaled approximately $225 million as of June 30, 2025 Cash resources totaled approximately $225 million as of June 30, 2025
globenewswire.com
- 5 days ago
Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy
Abeona will receive a license payment and potential development, regulatory, and sales milestones, and royalties Abeona will receive a license payment and potential development, regulatory, and sales milestones, and royalties
globenewswire.com
- 6 days ago
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, July 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
globenewswire.com
- 6 days ago
Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index
CLEVELAND, June 30, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it was added as a member of the U.S. small-cap Russell 2000® Index and the broad-market Russell 3000® Index as part of the reconstitution of the Russell stock indexes, effective at the open of the U.S. equity markets today.
globenewswire.com
- 1 week ago
Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa
- RDEB is a lifelong debilitating, blistering skin disease associated with large and painful wounds that often remain open for years and cause significant clinical burden, including pain, itch, and risk of squamous cell carcinoma -
globenewswire.com
- 1 week ago
Squarepoint Ops LLC Buys New Position in Abeona Therapeutics Inc (NASDAQ:ABEO)
Squarepoint Ops LLC bought a new position in Abeona Therapeutics Inc (NASDAQ:ABEO – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 12,028 shares of the biopharmaceutical company’s stock, valued at approximately $67,000. Other institutional investors and hedge funds have also recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Abeona Therapeutics by 20.1% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company’s stock valued at $21,736,000 after buying an additional 652,366 shares in the last quarter. 683 Capital Management LLC raised its position in Abeona Therapeutics by 17.3% in the 4th quarter. 683 Capital Management LLC now owns 791,845 shares of the biopharmaceutical company’s stock worth $4,411,000 after buying an additional 116,845 shares during the last quarter. Bank of America Corp DE raised its position in Abeona Therapeutics by 16.7% in the 4th quarter. Bank of America Corp DE now owns 264,439 shares of the biopharmaceutical company’s stock worth $1,473,000 after buying an additional 37,774 shares during the last quarter. Northern Trust Corp grew its stake in shares of Abeona Therapeutics by 6.6% during the 4th quarter. Northern Trust Corp now owns 184,929 shares of the biopharmaceutical company’s stock valued at $1,030,000 after purchasing an additional 11,478 shares during the period. Finally, Jane Street Group LLC grew its stake in shares of Abeona Therapeutics by 894.8% during the 4th quarter. Jane Street Group LLC now owns 131,478 shares of the biopharmaceutical company’s stock valued at $732,000 after purchasing an additional 118,262 shares during the period. Institutional investors own 80.56% of the company’s stock. Abeona Therapeutics Stock Performance Shares of NASDAQ:ABEO opened at $6.46 on Wednesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. The business’s 50 day moving average price is $5.62 and its 200-day moving average price is $5.58. The firm has a market capitalization of $330.47 million, a PE ratio of -2.40 and a beta of 1.54. Abeona Therapeutics Inc has a 1 year low of $3.93 and a 1 year high of $7.32. Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) last posted its earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.11. As a group, equities research analysts expect that Abeona Therapeutics Inc will post -1.16 earnings per share for the current fiscal year. Wall Street Analysts Forecast Growth A number of research firms have issued reports on ABEO. Stifel Nicolaus cut their price target on Abeona Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Friday, May 16th. Alliance Global Partners restated a “buy” rating on shares of Abeona Therapeutics in a report on Thursday, May 15th. HC Wainwright upped their price objective on Abeona Therapeutics from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, April 30th. Wall Street Zen downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 15th. Finally, Oppenheimer began coverage on Abeona Therapeutics in a research report on Monday, June 2nd. They issued an “outperform” rating and a $19.00 price objective on the stock. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Abeona Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $19.25. Read Our Latest Stock Report on ABEO Insider Buying and Selling In related news, CFO Joseph Walter Vazzano sold 17,795 shares of the company’s stock in a transaction dated Friday, June 6th. The stock was sold at an average price of $6.76, for a total value of $120,294.20. Following the completion of the sale, the chief financial officer now directly owns 491,246 shares of the company’s stock, valued at $3,320,822.96. This represents a 3.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Vishwas Seshadri sold 25,000 shares of the stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $4.78, for a total value of $119,500.00. Following the transaction, the chief executive officer now directly owns 1,355,322 shares of the company’s stock, valued at approximately $6,478,439.16. This trade represents a 1.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 113,941 shares of company stock valued at $711,341 in the last three months. 6.90% of the stock is owned by corporate insiders. Abeona Therapeutics Company Profile (Free Report) Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. See Also Five stocks we like better than Abeona Therapeutics About the Markup Calculator AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway Canadian Penny Stocks: Can They Make You Rich? Casey’s Surges on Strong Q4, More Gains Likely Ahead Insider Trading – What You Need to Know Government Mandate Sends eVTOL Stocks Flying
https://www.defenseworld.net
- 3 weeks ago
Abeona Therapeutics: Substantially Undervalued Post-FDA Approval (Rating Upgrade)
Abeona's ZEVASKYN approval and a $3.1 million price point are undervalued by the market, especially after a $152 million PRV sale bolstered cash reserves. Conservative launch modeling, including risk-adjusted revenue and single-treatment assumptions, still yields a fair value 36%+ above the current share price. Execution of outcome-based payer agreements and a strong cash position de-risk the launch, while competition and reimbursement remain manageable concerns.
seekingalpha.com
- 1 month ago
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, June 02, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
globenewswire.com
- 1 month ago
Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference
CLEVELAND, May 30, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Ph.D., Chief Executive Officer, and Madhav Vasanthavada, Ph.D., Chief Commercial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 11:40 a.m. Eastern Time.
globenewswire.com
- 1 month ago
Abeona Therapeutics Inc. (ABEO) Q1 2025 Earnings Call Transcript
Abeona Therapeutics Inc. (NASDAQ:ABEO ) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Greg Gin - Vice President-Investor Relations and Communications Vish Seshadri - Chief Executive Officer Madhav Vasanthavada - Chief Commercial Officer and Head-Business Development Brian Kevany - Chief Technical Officer Joe Vazzano - Chief Financial Officer Conference Call Participants Rick Miller - Cantor Fitzgerald Steven Willey - Stifel Ram Selvaraju - H.C. Wainwright James Molloy - Alliance Global Partners David Bautz - Zacks Small Cap Research Operator Good day and welcome to the Abeona Therapeutics First Quarter 2025 Conference Call.
seekingalpha.com
- 1 month ago
Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates
- Received approval by U.S. Food and Drug Administration (FDA) for ZEVASKYN™ (prademagenezamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adultand pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB) - - U.S. launch of ZEVASKYN underway with activation of first qualified treatment center (QTC) - - Entered into sales agreement for priority review voucher (PRV) for $155 million - CLEVELAND, May 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results and business highlights for the first quarter of 2025 and shared recent operational progress. “ZEVASKYN's approval just a few weeks ago is a landmark achievement for recessive dystrophic epidermolysis bullosa patients and signifies Abeona's transition to a commercial-stage cell and gene therapy company,” said Vish Seshadri, Chief Executive Officer of Abeona.
globenewswire.com
- 1 month ago
UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder
- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. -
globenewswire.com
- 1 month ago
8. Profile
Summary
Abeona Therapeutics Inc. ABEO
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 301 M
Dividend Yield
0.00%
Description
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Contact
1330 Avenue of the Americas, Cleveland, NY, 10019
https://www.abeonatherapeutics.com
IPO
Date
Sept. 19, 1980
Employees
136
Officers
Mr. Joseph Walter Vazzano CPA
Chief Financial Officer
Dr. Brendan M. O'Malley J.D., Ph.D.
Chief Legal Officer
Mr. Jon Voss
Vice President & Head of Quality
Dr. Madhav Vasanthavada M.B.A., Ph.D.
Senior Vice President, Chief Commercial Officer & Head of Business Development
Mr. Carl Denny
Senior Vice President of Regulatory Affairs
Ms. Alison Hardgrove
Chief People Officer
Mr. Gregory Gin
Vice President of Investor Relations & Corporate Communications
Dr. Vishwas Seshadri M.B.A., Ph.D.
President, Chief Executive Officer & Director
Mr. Brian Kevany Ph.D.
Senior Vice President, Chief Technology Officer & CSO